China patent law change helps local innovation

12 January 2009

The sixth session of 11th National People's Congress Standing Committee has approved, by 154 votes in favor and four abstentions, to amend  China's Patent Law to encourage local R&D. Under the latest revision of  the legislation, originally adopted in 1985, applications will be  allowed to be filed outside China before being made domestically,  although there is a requirement for scrutiny by a government agency to  determine if a national security restriction should be imposed.

Chen Guangjun, a spokesman for the NPC's Education, Science, Culture and  Health Committee, told reporters that the changes will improve China's  international competitiveness. The new policy means that firms  conducting R&D in China will find it easier to obtain intellectual  property protection worldwide. Filings increased over 32% in 2006.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight